021-51111890
购物车（）
sales@molnova.cn
OSU-2S
CAS No. 1351056-65-9
OSU-2S ( OSU 2S )
产品货号. M11419 CAS No. 1351056-65-9
一种非免疫抑制性 FTY720 类似物，PKCδ 激活剂，具有更高的抗增殖效力。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称OSU-2S
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种非免疫抑制性 FTY720 类似物，PKCδ 激活剂，具有更高的抗增殖效力。
-
产品描述A non-immunosuppressive FTY720 analogue, PKCδ activator with higher antiproliferative potency with IC50 of 2.4, 2.4, and 3.5 uM in Huh7, Hep3B, and PLC5 cells, respectively; exhibited higher in vitro antiproliferative efficacy relative to FTY720 against HCC cells without cytotoxicity in normal hepatocytes, although devoid of S1P1 receptor activity; induces caspase-dependent apoptosis through ROS-dependent PKCδ activation in HCC tumor cells.
-
体外实验Cell Proliferation AssayCell Line:Hep3B, Huh7, PLC-5, HepG2 cells Concentration:0-10 μM Incubation Time:48 h Result:Showed anti-proliferative effects with IC50s of 2.53, 2.41, 3.96, 1.84 μM for Hep3B, Huh7, PLC-5, HepG2 cells, respectively.Western Blot Analysis Cell Line:Hep3B cells Concentration:1.25, 2.5 μM combinated with sorafenib (2.5, 5 μM)Incubation Time:48 h Result:Decreased the expression of ERK1/2 phosphorylation, increased the expression of PKCδ (38 kDa) when sorafenib/OSU-2S combination.
-
体内实验Animal Model:CD2F1 mice (Hep3B tumor xenograft models)Dosage:5, 10 mg/kg Administration:I.p.; once daily for 42 days Result:Exhibited a higher tumor-suppressive potency, achieving 80% reduction in bioluminescence at the end of treatment.
-
同义词OSU 2S
-
通路Angiogenesis
-
靶点PKC
-
受体PKC
-
研究领域——
-
适应症——
化学信息
-
CAS Number1351056-65-9
-
分子量335.532
-
分子式C21H37NO2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCCC[C@@](CCC1=CC=C(OCCCCCC(C)C)C=C1)(N)CO.[H]Cl
-
化学全称(S)-2-amino-2-(4-[(6-methylheptyl)-oxy]phenethyl)pentan-1-ol
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
-
ZIP
Novel, cell-permeable inhibitor of protein kinase Mζ (PKMζ), a constitutively active, atypical PKC isozyme involved in LTP maintenance. Selectively blocks PKMζ-induced synaptic potentiation in hippocampal slices in vitro. Reverses late-phase LTP (IC50 = 1 - 2.5 μM) and produces persistent loss of 1-day-old spatial memory following central administration in vivo.
-
PKC-theta inhibitor
PKC-theta 抑制剂是 PKC-θ 抑制剂，IC50 为 12 nM。
-
20-HETE
20-HETE promotes cell proliferation and migration in cancer and can be used to study prostate tumors and cardiac hypertrophy by activating the protein kinase C pathway to increase FBXO10 expression.20-HETE promotes cell proliferation and migration in cancer and can be used to study prostate tumors and cardiac hypertrophy by activating the protein kinase C pathway.
